Bergen Brunswig Corporation Announces Prime Vendor Contract With InSource Health Services
Under terms of the new agreement, which will commence January 22, 2001, BBDC will be one of InSource's Preferred Authorized Distribution Agents to provide pharmaceuticals to both their acute and alternate care facilities. This agreement builds on Bergen's previous relationship with InSource, which concentrated on the alternate care market segment.
"We are delighted that InSource has decided to expand its relationship with Bergen by extending our agreement to all facilities," said Doug Swanson, president, BBDC Health Systems.
Ed Gravell, President of InSource Health Services added, "This new distribution agreement demonstrates Bergen's commitment to InSource's mission of providing exceptional value to our membership while enhancing the relationship between Bergen and InSource. We are confident our members will take advantage of this new agreement that offers the quality service and innovative programs available from Bergen."
Over 10,000 facilities in 50 states make up InSource's membership, including acute care facilities and non-acute site providers (surgery centers, long-term care facilities, retirement centers, nursing homes, home health agencies, closed pharmacies, HMOs, dialysis units, and multi-disciplinary clinics).
Bergen Brunswig Corporation, headquartered in Orange County, California, is a leading supplier of pharmaceuticals and specialty healthcare products, as well as information management solutions and consulting services. Bergen's customers include the nation's healthcare providers (hospitals, nursing homes and physicians), drug stores, manufacturers and patients. Through its subsidiaries, Bergen provides product distribution; logistics; pharmacy management programs; and Internet fulfillment strategies designed to reduce costs and improve patient outcomes across the entire healthcare spectrum.
Except for historical information, all other information set forth in this press release, such as earnings forecasts and earnings rate projections, consists of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking statements" are subject to risks, uncertainties and other factors which could cause actual results to differ materially from those projected or implied. Such statements may be identified by the use of forward-looking language such as "may," "will," "should," expect," "anticipate," "estimate," "believe," "think," "continue" or the negatives or other variations thereof or other similar terminology. Such risks and uncertainties include the risks described in exhibit 99(a) to the Company's Annual Report on Form 10-K for the year ended September 30, 2000 and in other reports and exhibits filed with the Securities and Exchange Commission. These risks and uncertainties include, but are not limited to, the costs and difficulties related to the integration of acquired businesses, the loss or disruption of one or more key customer or supplier relationships, changes in the distribution outsourcing pattern for pharmaceutical products and/or services, the ability to obtain general financing or financing rates that would be compatible with the Company's business operations, and the costs and other effects of governmental regulation and legal and administrative proceedings. The Company assumes no obligation to update the information in the release.
Bergen Brunswig press releases are available on the company's website at www.bergenbrunswig.com.